To date, at least 1,000 mutations occurring in 64 genes in the human genome have been linked to hearing loss. Next-generation DNA sequencing technologies are enabling the identification of these deafness-causing genetic variants, as described in a Review article in Genetic Testing and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Genetic Testing and Molecular Biomarkers website.
In “Next-Generation Sequencing in Genetic Hearing Loss,” Denise Yan and Xue Zhong Liu, University of Miami (Florida), and Mustafa Tekin and Susan Blanton, University of Miami Miller School of Medicine, review the advances in high-throughput, massively parallel DNA sequencing that amplify and repeatedly sequence only specific regions of the human genome in which genes linked to deafness are likely to be found. This strategy, known as “targeted resequencing,” allows researchers to find disease-related gene mutations much more quickly than searching through the entire genome. To date at least 1,000 DNA variants at more than 130 sites in the human genome have been identified that can cause hearing loss not associated with other symptoms or syndromes.
“Over the next decade, most of the variant genes responsible for deafness will be identified and such knowledge will lead to the development of practical treatments,” conclude the authors.
“Knowledge of the genetic lesions underlying deafness will greatly assist development of targeted therapy,” says Kenneth I. Berns, MD, PhD, Editor-in-Chief of Genetic Testing and Molecular Biomarkers, and Director of the University of Florida’s Genetics Institute, College of Medicine, Gainesville, FL.
About the Journal
Genetic Testing and Molecular Biomarkers is an authoritative peer-reviewed journal published 12 times per year in print and online that reports on all aspects of genetic testing, including molecular and biochemical based tests and varied clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. Tables of content and a free sample issue may be viewed on the Genetic Testing and Molecular Biomarkers website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy and OMICS: A Journal of Integrative Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.